Latest Lead News

Syrah Resources has resumed production and shipping from its Balama Graphite Operation in Mozambique, marking a significant step in restoring normal operations after earlier disruptions.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

QPM Energy has successfully raised $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $2 million target to accelerate key gas power projects in Queensland.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Sunshine Metals has launched an advanced scoping study targeting 95,000 ounces of gold and 652,000 ounces of silver at its Liontown project in North Queensland. The study aims to optimise extraction from multiple high-grade resource domains, with metallurgical test results expected in August 2025.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Magnetic Resources NL’s Feasibility Study confirms a robust standalone development for its Lady Julie Gold Project in Western Australia, projecting over 1 million ounces of gold production across nine years with strong financial returns.

Miramar Resources has announced a $1 million Share Purchase Plan to fast-track drilling at its promising 8 Mile gold prospect near Kalgoorlie, following recent significant mineralisation discoveries.

Condor Energy has secured a 12-month extension for its Technical Evaluation Agreement in Peru’s Tumbes Basin, underpinning its exploration and commercialisation plans backed by significant prospective oil and gas resources.

Bastion Minerals and former advisor GTT Ventures have resolved their legal dispute, leading to the withdrawal of a writ that had cast uncertainty over the company.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.